|
Patent landscape, scope, and claims summary: |
Patent Landscape Analysis of US Patent 10,000,553 (CD40L-Specific Tn3 Scaffold): Claims, Validity Hooks, and Competitive Risk
US 10,000,553 claims a CD40L-specific Tn3 scaffold built from a defined beta-strand plus loop architecture (AB, BC, CD, DE, EF, FG loops assigned to specific SEQ ID NOs or enumerated sets). The estate’s practical scope is driven by: (i) strict sequence/loop identification requirements in independent claim 1; (ii) defined multi-subunit and tandem constructions in dependent claims; (iii) narrow conjugation/fusion embodiments (PEG or HSA variant) in higher-numbered claims; and (iv) functional readouts that are likely treated as non-limiting if the sequence limitations already define the binding/disruption.
Immediate takeaways
- The strongest infringement and enforceability path is claim 1 because it is the only independent claim and it ties CD40L binding to specific loop sequences and beta-strand identities.
- Design-around is most plausible by substituting even one loop (AB/BC/CD/DE/EF/FG) with sequences not enumerated, or by using a different Tn3 architecture that still binds CD40L but does not literally satisfy the loop mapping.
- Claims covering tandem monomers, and PEG/HSA fusions expand coverage only if the accused product stays inside the enumerated SEQ ID NO framework (and in practice many CD40L binders will fail literal coverage unless engineered from the claimed backbone).
- Commercial entry risk for competitors is therefore pattern-specific: it is lower if they use alternative CD40L binders (mAbs, Fc-fusions, TNFR-like domains, or different scaffold technologies) and higher only if they have engineered sequence families that overlap these SEQ IDs.
What does US 10,000,553 claim: CD40L-specific Tn3 scaffold built from defined beta strands and loop sequences?
Claim 1 essentials (core structural limitation + functional binding)
Independent claim 1 requires a Tn3 scaffold with:
- A Tn3 scaffold with seven beta strands labeled A through G
- Six loop regions AB, BC, CD, DE, EF, FG
- A precise loop/strand mapping:
- AB loop = SEQ ID NO: 4
- BC loop = SEQ ID NO in {83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 168}
- CD loop = SEQ ID NO: 6
- DE loop = SEQ ID NO in {94, 95, 96, 97, 98, 169}
- EF loop = SEQ ID NO: 8
- FG loop = SEQ ID NO in {9, 99, 139, 170}
- The scaffold “specifically binds to CD40L”.
Critical point for infringement: even if a competitor binds CD40L, literal infringement depends on satisfying the enumerated sequence identity constraints. The “specifically binds” clause will typically not rescue a product that misses a required AB/BC/CD/DE/EF/FG sequence.
How the dependent claim set tightens scope
- Claim 2: two CD40L-specific monomer subunits connected in tandem.
- Claim 3: binding + prevention of CD40 binding and/or disruption of CD40 signaling (read as functional consequences, but again constrained by claim 1’s sequence requirements).
- Claim 4-6: allows conjugation/fusion of at least one monomer to heterologous moieties, with PEG or HSA variant (SEQ ID NO: 133) in claim 5-6.
- Claim 7: enumerates identities of the A-G beta strands by SEQ IDs (11-18), with flexibility for strand C (SEQ ID NO: 13 or 14).
- Claim 8: also limits to scaffolds whose sequences are in a defined list: SEQ ID NOs: 134, 135, 144, 145, 146, 166, 205, 206, 207, 208.
- Claim 9-10: method of altering CD40 signaling by contacting a CD40L-expressing cell, including T-dependent immune response limitation in claim 10.
- Claim 11: composition with pharmaceutically acceptable excipient.
- Claim 12-13: claim 12 is highly granular and is effectively a combinatorial enumeration of specific BC/DE/FG loop combinations with strand settings from claim 7. Claim 13 narrows the monomer subunit sequence further (list of SEQ IDs 20, 22, 24…42, 146).
- Claim 14-16: tandem monomers connected by a peptide linker, with linker being a (GmX)n motif under specific integer ranges and specific SEQ IDs (131, 132, 142, 143).
- Claim 17-19: additional specific SEQ ID scaffold/monomer coverage (SEQ ID NO: 145; monomer SEQ ID NO: 146).
Claim construction pressure points
- Sequence identity vs. “selected from”: Many loops are covered by sets. Competitors can still design around by selecting values outside each enumerated set (for AB and CD and EF, it is effectively fixed).
- Tandem vs. other oligomerization: Claim 2 covers “two … connected in tandem.” Dimers arranged in different topologies could fall outside literal scope.
- PEG/HSA scope: Claim 5-6 and claim 18 constrain PEG/HSA to particular structures/variants (HSA variant is sequence-defined). That limits claim breadth relative to generic “PEGylation” or “HSA fusion” approaches.
How many patents cover CD40L-Tn3 scaffolds like US 10,000,553, and where does this one fit?
Critical limitation on landscape reconstruction
A full multi-patent landscape requires bibliographic details (patent family members, assignee, publication numbers, continuation chain, and citations) and must be built from the patent record. This prompt provides only the claim text, not the patent’s assignee, filing history, or family data. Without those record anchors, a precise “how many patents” statement across the US and globally would be incomplete.
What can be concluded from the claim architecture alone
- The claim uses a Tn3 scaffold and a CD40L-specific monomer with explicit SEQ ID mapping. That claim style is typical of an engineering-focused IP package that often accompanies:
- early scaffold invention,
- binding-site sequence optimization,
- fusion/conjugate embodiments (PEG/HSA, tags),
- and therapeutic methods (CD40 signaling disruption; immune modulation).
- The presence of multiple loop variants and enumerated scaffold sequences suggests at least one optimization round with multiple candidate constructs, likely reflected in continuation practice. That said, the exact count and jurisdictional spread cannot be asserted without record data.
What patent validity risks exist for US 10,000,553 under obviousness and enablement theories?
Novelty pressure: scaffold platform vs. target-specific sequences
- If prior art already disclosed Tn3 scaffolds with loop/strand engineering paradigms, novelty may hinge on whether the specific CD40L-binding loop/strand sequences were previously known.
- Claim 1’s value is its specific loop SEQ ID lists. If prior art documents disclosed the same sequences as CD40L binders, anticipation risk rises.
- If prior art disclosed sequences that were close but not identical, the key question becomes whether a person of skill could converge on the enumerated loop combinations with predictable outcome.
Obviousness pressure: combinatorial enumeration
- Claim 12 enumerates many BC/DE/FG combinations. Enumeration can cut two ways:
- it can show the applicant actually tested/identified a favorable binding set,
- but it also can be attacked as obvious selection if the loop libraries were known and CD40L affinity was a predictable function.
- The DE and BC loops each include multiple SEQ IDs, implying multiple “allowed” replacements. If prior art presented a similar library and demonstrated CD40L binding across broad variants, obviousness risk increases.
Enablement and written description hooks
- Written description risk would be triggered if:
- the patent claims large “selected from” ranges without sufficient examples demonstrating CD40L-specific binding across all enumerated combinations; or
- it claims functional outcomes (preventing CD40 binding / disrupting signaling) without correlating data to show that all claimed variants achieve the stated functional effects.
- Because claim 1 already narrows binding through specific loop sequences, enablement typically improves relative to broader, non-sequence-defined binding claims.
When does US 10,000,553 expire and what exclusivity milestones matter for CD40L binders?
Exclusivity timeline limitations
A binding exclusivity timeline (patent term end date) requires:
- filing date, priority dates, and patent term adjustment, and
- whether it is subject to PTA limitations and any terminal disclaimer.
Those data are not provided. This analysis therefore cannot produce an accurate expiration date or court-structured timeline.
Practical impact for business planning
- For scaffold-based biologics, the effective exclusivity cliff is often dictated less by general patent-term math and more by:
- whether there is a continuation family that extends claims,
- whether there are method-of-use patents that delay exclusivity for specific mechanisms, and
- whether regulatory exclusivity (e.g., composition-specific exclusivity, BLA/IND exclusivity) applies alongside patents.
What would an FDA Orange Book or biosimilar-style risk look like for a Tn3 CD40L binder?
Orange Book mismatch risk
US CD40L Tn3 scaffolds are protein biologics. The Orange Book lists approved drug products for which patents are submitted for FDA approval. Many biologic protein binders instead land under the biologics licensing framework, where patent listings can function differently and where biosimilar pathways matter.
Biosimilar vs generic entry
- A Tn3 scaffold CD40L binder would likely be evaluated as a biologic (depending on size and regulation classification).
- A “generic” entry is generally constrained for biologics; instead, biosimilar and sometimes “interchangeable” pathways can matter.
- Patent risk hinges on whether any biosimilar candidate uses the claimed sequences or structural equivalents that meet the sequence-specific claim boundaries.
Because the claims are sequence-defined, biosimilar-style “functional equivalence” arguments are less likely to defeat literal sequence limitations, unless the biosimilar engineering yields claimed loop/strand identities.
Where can competitors design around this estate with high confidence?
Loop substitution design-around
Claim 1 is the key barrier. If the competitor:
- changes AB loop away from SEQ ID NO: 4, or
- changes CD loop away from SEQ ID NO: 6, or
- changes EF loop away from SEQ ID NO: 8,
then literal infringement is avoided.
For the variable loops:
- change BC to a sequence not in {83-93,168}
- change DE to a sequence not in {94-98,169}
- change FG to a sequence not in {9,99,139,170}
Topology design-around
- Use a non-tandem arrangement instead of “two … connected in tandem” (claim 2).
- Use linker chemistries and motifs outside the claimed (GmX)n constraints and enumerated SEQ IDs for linkers (claim 14-16).
Conjugate/fusion design-around
- Avoid PEGylation or HSA variants that do not meet the specific PEG/HSA embodiments claimed (claim 5-6 and claim 18).
- If fusing to HSA, use a non-SEQN0:133 variant or different fusion design that escapes literal definition.
Sequence-list design-around
- Claims 7 and 8 add additional exact SEQ ID enumerations (beta strand SEQ IDs; full scaffold SEQ ID list). If a competitor avoids those full-sequence identities, it can avoid multiple dependent claims simultaneously.
What patent litigation risks would matter for a CD40L Tn3 scaffold product?
Litigation exposure is claim-sensitivity-driven
In scaffold patents with strong sequence definitions:
- plaintiffs often rely on sequence comparison and structure mapping,
- and defendants typically attack by asserting that their product uses different loop sequences or different scaffold identities.
Settlement dynamics typically observed
Where sequence-locked claims are asserted:
- settlement can include cross-licenses limited to certain sequence families,
- or covenant not to sue for alternative scaffolds outside the literal claim set.
But settlement specifics cannot be derived from the information provided.
How does this patent’s claim structure compare with typical CD40L biologic IP estates?
Monoclonal antibodies (mAbs)
mAb patent estates generally cover:
- antibodies defined by CDR sequences or binding epitopes,
- Fc engineering and effector function modifications,
- and diagnostic or combination uses.
US 10,000,553 instead covers:
- a scaffold with explicit loop SEQ IDs,
- and functional disruption of CD40L-CD40 signaling.
This makes it more sequence-formal than many epitope-defined mAb claims.
Receptor decoys (CD40/Fc-like proteins)
Receptor decoys typically claim:
- decoy fusion proteins, often defined by domain composition rather than strict loop-by-loop sequences.
A Tn3 loop-defined approach narrows infringement to near identity in structure and sequence.
Key claim-by-claim business implications (where value is created, and where it leaks)
| Claim |
Coverage type |
Biggest value |
Primary leak route |
| 1 |
Independent, sequence-defined scaffold with enumerated loops |
Establishes enforceable “center of mass” on CD40L binding Tn3 loop set |
Change any fixed loop (AB/CD/EF) or swap loops outside allowed sets |
| 2 |
Tandem dimer topology |
Extends coverage to multivalent constructs |
Use non-tandem dimer or alternate multimerization |
| 3 |
Functional disruption of CD40 signaling |
Helps frame therapeutic effect |
Hardest functional claims may be treated as satisfied only if sequence requirements met; otherwise irrelevant |
| 4 |
Broad heterologous fusion/conjugate list |
Enables many downstream commercialization variants |
Slip outside the listed moiety types or avoid fusion/conjugate while keeping binder |
| 5-6 |
PEG or specific HSA variant (SEQ ID NO:133) |
Protects common half-life extension path |
Use different PEG chemistry or different HSA variant/fusion architecture |
| 7 |
Beta strand SEQ ID mapping |
Locks scaffold backbone identity |
Use different strand sequences not matching SEQ IDs |
| 8 |
Full scaffold SEQ ID list |
Strong, litigation-friendly infringement anchor |
Avoid exact scaffold sequence IDs |
| 9-10 |
Methods: altering CD40 signaling; T-dependent immune response |
Supports medical and combination use licensing |
Use different mechanism or target cell context; still constrained by claim 1 sequence |
| 11 |
Composition |
Broad formulation coverage |
Formulation changes that avoid literal composition claims can limit impact |
| 12-13 |
Fine-grained BC/DE/FG combinations and monomer sequence sets |
Captures preferred optimized constructs |
Choose loop combinations outside the enumerated matrix |
| 14-16 |
Tandem linker constraints |
Protects manufacturable constructs |
Use different linker motif/sequence not in SEQ ID list |
| 17-19 |
Additional specific scaffold/monomer SEQ IDs |
Strengthens overlap on specific commercial candidates |
Avoid those exact SEQ IDs |
Key Takeaways
- US 10,000,553 is a sequence-defined CD40L-binding Tn3 scaffold patent. The claim set is built around fixed loops (AB/CD/EF) and enumerated alternatives for BC/DE/FG, with additional tightening through beta-strand SEQ IDs, full scaffold SEQ IDs, tandem architecture, and PEG/HSA fusion embodiments.
- Enforceability and infringement risk primarily track whether an accused product uses the same loop and strand sequence identities. Competitive disruption by “functional equivalence” alone is unlikely to overcome explicit SEQ ID limitations.
- The design-around surface is wide at the loop level: shifting any fixed loop off its listed SEQ ID, or moving variable loops outside enumerated sets, can avoid literal infringement.
- The business question is not “does it bind CD40L,” but “does it instantiate the claimed loop/strand SEQ ID configuration,” including the dependent claim topology and fusion/linker limitations.
FAQs
What part of claim 1 is most critical to literal infringement for US 10,000,553?
The required loop identities: AB = SEQ ID NO: 4, CD = SEQ ID NO: 6, EF = SEQ ID NO: 8, plus BC/DE/FG being within the enumerated SEQ ID sets.
Can a competitor avoid infringement by changing only the BC loop?
Yes, if the BC sequence is changed to a value not in the claim 1 BC list (SEQ IDs 83-93 and 168). A CD40L binder with a BC loop outside the enumerated set avoids claim 1 literal scope.
Do tandem constructs automatically infringe if they bind CD40L?
No. Tandem topology is only claimed in claim 2, which is dependent on claim 1. The accused tandem must still satisfy claim 1’s loop/sequence limitations.
Is PEGylation or HSA fusion broadly covered in this patent?
PEG/HSA is covered only within the dependent claim embodiments. In particular, HSA variant is tied to SEQ ID NO: 133, and specific linker/connective constructs may be required.
Does the “disrupts CD40 signaling” language broaden coverage beyond the sequence limitations?
Practically, it does not override the explicit structural/sequence requirements of claim 1. A product that misses the claimed loop/strand identities will not be covered even if it disrupts CD40 signaling through a different scaffold.
References (APA)
- Claims text provided in the prompt for US Patent 10,000,553 (CD40L-specific Tn3 scaffold), including SEQ ID NO mappings and dependent claim feature lists.
More… ↓
⤷ Start Trial
|
